Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of AAV2/5-OPTIRPE65 gene therapy in RPE65-associated retinal dystrophy
2016-000898-20Phase 2Unknown
- Sponsor
- MeiraGTx
- Start
- Jan 2017
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cevaretigene ritoparvovec in Leber congenital amaurosis (LCA) and RPE65 deficiency, sponsored by MeiraGTx. Primary endpoints: Long-term safety of subretinal AAV2/5-OPTIRPE65, Visual acuity assessment and 1 more. Status: unknown.
02
Drugs
cevaretigene ritoparvovec
03
Conditions
Leber congenital amaurosis (LCA)RPE65 deficiency
Beyond the preview
Go deeper on 2016-000898-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000898-20.